Kwality Pharmaceuticals Limited Q2 FY27 Earnings Conference Call Summary
Key Financial Figures & Performance Highlights
Q2 FY27 Financial Performance (Consolidated):
- Revenue stood at ₹181 crores, representing a 63% year-on-year growth from ₹111 crores in Q2 FY26.
- EBITDA Margin expanded to 27.5%.
- Profit After Tax (PAT) doubled to ₹29 crores.
The strong performance was attributed to improved operating leverage and a robust product mix.
H1 FY27 Financial Performance:
- Revenue for the first half of the fiscal year stood at ₹343 crores.
Revised Guidance & Forward-Looking Commentary
Management provided updated financial guidance based on strong business momentum:
- FY27 Revenue Guidance: Revised upwards to ₹720 crores plus, from a previous guidance of ₹700 crores. Management indicated that ₹750 crores is an achievable internal target, but the official guidance was kept conservative.
- Long-Term Targets: The company is targeting revenue of ₹950 crore to ₹1,000 crores or more for FY28. For FY29, management expects a further 25%-30% growth from the FY28 base.
- EBITDA Margin Target: The company aspires to achieve a 30% EBITDA margin by FY29, driven by an improvement in gross margins to 54%-55% and operating leverage.
Operational & Strategic Updates
Regulatory and Manufacturing Milestones:
- Received European-GMP certification from Hungary for the cephalosporin and oncology facility.
- Completed bioequivalence (BE) studies for 19 out of 40 targeted molecules for global filing. Dossiers for these 19 products are ready.
- Acquired four acres of land for the proposed Unit 7 manufacturing facility, earmarked for future growth and bioequivalence product commercialization.
Progress on Specific Business Verticals:
- Bioequivalence Products: The first 7-8 molecules are expected to be commercialized in FY28, contributing an estimated ₹80-90 crores in revenue. The full portfolio of 19 products is projected to generate around ₹300 crores in revenue by FY29.
- Cephalosporin Facility: Filed for registrations in Mexico (expected in Q4 FY27), Brazil (expected in Q2 FY28), and Europe. The company is in discussions with a U.S.-based company for an ANDA filing for cephalosporin products, with potential commercialization of 1-2 products in the U.S. market by FY30.
- Hormone Facility: Targeting commercialization starting in Q2 FY28, with an estimated revenue potential of ₹100-150 crores by FY29.
- Biologics/Biosimilars:
- Erythropoietin: Already commercialized in some markets (e.g., Egypt) via biowaiver applications, contributing 1% of revenue in Q2. Targeted revenue is ₹30-40 crores in FY28 and ₹80-100 crores by FY29. The long-term potential for this molecule alone is estimated at nearly ₹1,000 crores.
- Pipeline: Other molecules in development include Pembrolizumab, Nivolumab, and Pertuzumab. Biowaiver applications for Pembrolizumab are targeted for January 2027.
- CDMO: Applied for a CDSCO 27D license to enable biological fill-to-finish CDMO work, expected by December 2026 or January 2027.
Working Capital Improvement:
The company reported a significant improvement in its working capital cycle, reducing it to 130 days from 170 days in FY26. Debtor days were reduced from 208 days to 178 days.
Capital Expenditure (Capex) & Funding Plans
- The ongoing capex plan of ₹140-150 crores is nearly complete, with ₹20-25 crores pending, expected to be finished by April 2027.
- The next phase of capex for Unit 7 and future bioequivalence studies is estimated at ₹200-250 crores for the facility and ₹250-300 crores for 200 BE studies over three years (FY28-FY30).
- This expansion is planned to be funded primarily through internal accruals and retained earnings, with some bank funding if needed. Management stated there are no current plans for equity dilution.
Question & Answer Highlights
Growth Trajectory: Management confirmed that the ₹1,000 crore FY29 target is conservative and that reaching ₹950-1,000 crores in FY28 is a possibility, dependent on the pace of product registrations, particularly in Europe and Brazil.
Market Focus & Margins: The company is shifting focus towards more profitable regulated markets (LATAM, Europe) and away from less profitable regions affected by geopolitical issues. Margins are higher (28%-32% EBITDA) on products where Kwality holds its own Marketing Authorizations (MA) compared to partner-held MA products (24%-26% EBITDA).
R&D Spend: R&D expenditure is planned to scale from 2.5% of revenue to 5%-6%. The target EBITDA margin of 30% by FY29 is expected to be achieved alongside this increase through improved gross margins and operating leverage.
Tax Rate: A question was raised about a higher tax rate in Q2, but management deferred a detailed response, stating it would be addressed by the company secretary.
Corporate Actions: Management confirmed there are no current plans for a stock split, bonus issue, or dividend, as earnings are being prioritized for funding expansion plans.
Compliance Update: KPMG has been appointed as the new auditor.